Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Total Liabilities (2021 - 2026)

HeartSciences (HSCS) has disclosed Total Liabilities for 5 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 51.77% year-over-year to $1.8 million, compared with a TTM value of $1.8 million through Oct 2025, down 51.77%, and an annual FY2025 reading of $4.0 million, up 83.81% over the prior year.
  • Total Liabilities was $1.8 million for Q4 2025 at HeartSciences, down from $3.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $8.1 million in Q2 2022 and bottomed at $1.8 million in Q4 2025.
  • Average Total Liabilities over 5 years is $3.4 million, with a median of $3.4 million recorded in 2021.
  • The sharpest move saw Total Liabilities crashed 62.47% in 2023, then soared 83.81% in 2025.
  • Year by year, Total Liabilities stood at $3.4 million in 2021, then increased by 7.14% to $3.7 million in 2022, then grew by 8.95% to $4.0 million in 2023, then decreased by 6.41% to $3.8 million in 2024, then plummeted by 51.77% to $1.8 million in 2025.
  • Business Quant data shows Total Liabilities for HSCS at $1.8 million in Q4 2025, $3.3 million in Q3 2025, and $4.0 million in Q2 2025.